Table 3.

Summary of Studies Comparing Area Under the Curve to Minimum Inhibitory Concentration Ratio to Clinical Outcomes in Patients With Staphylococcus aureus Infection

Study [Reference]	Study Characteristics	MIC Method	Outcome/Comments
Moise-Broder et al [23]	Retrospective study of MRSA/MSSA hospital-acquired pneumonia (n = 50)	BMD	AUC/MIC ≥350 associated with clinical success (OR, 7.2; 95% CI, 1.9–27)
Jeffres et al [68]	Retrospective study of MRSA healthcare-associated pneumonia	Inferreda	None of the AUC strata (<200; 201–300; 301–400; >400) were associated with better outcomes
Kullar et al [69]	Retrospective study of MRSA bacteremia (n = 320)	Etest	AUC/MIC <421 was associated with increased failures (composite endpoint of 30-d mortality, persistent bacteremia, and ongoing symptoms)
Brown et al [70]	Retrospective study of complicated MRSA bacteremia and IE (n = 50)	Etest	AUC/MIC <211 was associated with attributable mortality (OR, 10.4; 95% CI, 3.9–16.8)
Neuner et al [71]	Retrospective study of MRSA bacteremia (n = 222)	Etest	AUC/MIC did not correlate with the presence of persistent bacteremia
Holmes et al [26]	Retrospective cohort study of patients with MRSA bacteremia	BMD	AUC/MIC> 373 was associated with reduced mortality (OR, 0.44; 95% CI, .2–.99)

Abbreviations: AUC/MIC, area under the serum drug concentration curve to minimum inhibitory concentration ratio; BMD, broth microdilution; CI, confidence interval; IE, infective endocarditis; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; OR, odds ratio.

^a Vancomycin MIC was inferred from the results obtained by disk diffusion, which is no longer considered an accepted susceptibility method (see Table 2).